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Background: Activin A, an important member of transforming growth factor-β superfamily, is reported to inhibit
proliferation of mature hepatocyte. However, the effect of activin A on growth of hepatic progenitor cells is not fully
understood. To that end, we attempted to evaluate the potential role of activin A in the regulation of hepatic
progenitor cell proliferation.
Results: Using the 2-acetaminofluorene/partial hepatectomy model, activin A expression decreased immediately
after partial hepatectomy and then increased from the 9th to 15th day post surgery, which is associated with the
attenuation of oval cell proliferation. Activin A inhibited oval cell line LE6 growth via activating the SMAD signaling
pathway, which manifested as the phosphorylation of SMAD2/3, the inhibition of Rb phosphorylation, the suppression
of cyclinD1 and cyclinE, and the promotion of p21WAF1/Cip1 and p15INK4B expression. Treatment with activin A antagonist
follistatin or blocking SMAD signaling could diminish the anti-proliferative effect of activin A. By contrast, inhibition of the
MAPK pathway did not contribute to this effect. Antagonizing activin A activity by follistatin administration enhanced oval
cell proliferation in the 2-acetylaminofluorene/partial hepatectomy model.
Conclusion: Activin A, acting through the SMAD pathway, negatively regulates the proliferation of hepatic
progenitor cells.
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Oval cells are regarded as adult liver progenitor cells. They
are able to differentiate either into mature hepatocytes or
biliary epithelial cells [1]. These cells are termed as “oval
cells” due to their characteristic morphology with an ovoid
nucleus, small size (relative to hepatocytes) and high nu-
clear to cytoplasmic ratio [1,2]. In the 2-acetaminofluorene
(2-AAF)/partial hepatectomy (PH) model, hepatocyte pro-
liferation is efficiently suppressed by 2-AAF. This forces
liver regeneration to become dependent on the replication
and differentiation of oval cells [3,4]. After the restoration
of the normal liver mass, any excess oval cells that have
failed to differentiate into mature hepatocytes stop* Correspondence: chenxp@medmail.com.cn
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reproduction in any medium, provided the orreplicating and are eliminated through apoptosis to pre-
vent liver hyperplasia [5]. The complex molecular events
that trigger liver regeneration are now beginning to be elu-
cidated [6], but little is known about the mechanisms that
restrict proliferation and return oval cell to quiescence
after liver regeneration.
Transforming growth factor-β1 (TGF-β1) has been pro-
posed to negatively regulate the proliferation of hepato-
cytes [7] and oval cells [8-10] but its role is controversial.
TGF-β1 over-expression results in impairment of oval cell
expansion in vivo, inhibiting growth and inducing apop-
tosis in oval cell lines in vitro [10,11]. Conversely, other
groups have demonstrated that TGF-β1 signaling is not
necessary for restricting hepatocyte proliferation [12]. Fur-
thermore, compared to hepatocytes, hepatic progenitor
cells (HPCs) are more resistant to the anti-proliferative ef-
fects of TGF-β1 [9]. These data imply that there may betd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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effect of TGF-β1 in the regulation of oval cell liver
regeneration.
Activin A, composed of two activin-βA subunits, is a
member of the activin family, which in turn is part of the
larger TGF-β superfamily. Activin A binds to its specific
activin type II receptors (ActRIIA and ActRIIB), which
leads to the recruitment and trans-phosphorylation of the
partner activin type I receptor (ALK4). Activated ALK4 re-
cruits and phosphorylates cytoplasmic receptor-regulated
SMADs (R-SMAD), SMAD2 and SMAD3, which form a
heterotrimer with SMAD4 (co-SMAD) and translocate into
the nucleus where they control gene transcription [13].
Activin A has been shown to suppress proliferation and in-
duce apoptosis of mature murine hepatocytes in vivo
and in vitro by up-regulating p21WAF1/Cip1, p15INK4B
and down-regulating cyclin D1 and Cyclin-Dependent
Kinase expression, and dephosphorylating Rb [14-18].
Moreover, intravenous or intraportal administration of
follistatin, a specific antagonist of activin A, can acceler-
ate liver regeneration in partially hepatectomized rats
[14-17]. Never-the-less, the role of activin A in the
regulation of hepatic oval cell proliferation has yet to be
fully elucidated. In order to reveal the action and mech-
anism of activin A on hepatic oval cell proliferation, we
first tested the expression pattern of activin A and follis-
tatin in the 2-AAF/PH model. We then evaluated the
response of a hepatic oval cell line to activin A in vitro.
Finally, we blocked activin A activity by intra-portal ad-
ministration of follistatin in the 2-AAF/PH model, and
measured hepatic oval cell proliferation to demonstrate
that activin A is an important negative regulator of hep-
atic oval cell mediated liver proliferation.Results
Expression pattern of activin A and follistatin in
2-AAF/PH model
We evaluated the spreading of HPCs in 2-AAF/PH model
using immuno-histochemical staining for Pan-Cytokeratin
(Pan-CK), which is an established marker of HPC’s [18].
Recent studies have reported the activation of pan-CK
positive HPCs in a number of HPC proliferation models
including the 2-AAF/PH model [19-21]. In normal control
and 2-AAF-treated sham operative rat liver, pan-CK
mainly labeled interlobular and terminal duct cells. In the
2-AAF/PH model, high nuclei/cytoplasm ratio pan-CK
positive cells (HPCs) initially appeared close to pre-
existing bile ducts in or around portal tracts (Figure 1B).
These cells became more numerous with time and
reached a peak on the 9th day after PH (Figure 1C and
M). From the 12th day to the 15th day post-surgery, the
tubular structures and numbers of pan-CK positive cells
dramatically decreased (Figure 1D and M), reaching anadir between the 18th day to 21st day post-surgery
(Figure 1M).
We next measured the expression of activin A and
follistatin by immunohistology. Activin A expression
showed no significant change until the 9th day, and
then increased rapidly and reached a peak on the 12th
day after surgery (Figure 1F to H and N). Follistatin
level increased on the first day after surgery and was
sustained until the 4th day (Figure 1J to L and O).
The transcript level of activin βA and follistatin
mRNA did not vary dramatically in the sham operation
group. Activin βA mRNA production decreased below
baseline from 6 hours to 9 days following PH (P < 0.05),
then increased from the 12th to 15th day after surgery,
when the number of pan-CK positive HPCs began to
decline (P < 0.01) (Figure 1P). Follistatin mRNA in-
creased as soon as 6 hours after PH, (P < 0.05), and
reached a peak at 24 hours (P < 0.05). After the peak, it
declined below baseline from the 2nd day to 9th day
after surgery (P < 0.01), then returned to the initial level
on the 12th day (Figure 1Q). Activin βA mRNA expres-
sion decreased and its endogenous antagonist follistatin
increased during the first phase of HPC dependent liver
regeneration, while HPCs dramatically proliferated. At
the end of the second week, the increase in activin βA
expression coincided with the decline in HPCs. From
these data, we presume that the activin A/follistatin axis
may play an important role in the regulation of HPCs
after partial hepatectamy.
Activin A suppresses HPCs proliferation in vitro
In order to confirm our hypothesis, we tested the effect
of exogenous activin A on cells from the rat HPC cell
line LE6. First, we examined the baseline of endogen-
ous activin A and TGF-β1 in LE6 cells by enzyme-
linked immunosorbent assay (ELISA). Any activin A
secreted by LE6 cell cultures was below the minimum
detectable dose of the ELISA kit (data not shown). LE6
cells secreted detectable quantities of TGF-β1 which
amounted to 60 pg/ml in the culture supernatants, and
the addition of exogenous activin A to the cell cultures
did not alter their expression of either activin A or
TGF-β1 (Figure 2A). Therefore, we could ignore the
interference of endogenous activin A and TGF-β1.
Next, we treated LE6 cells with various doses of ex-
ogenous activin A and measured the effect of this cyto-
kine on LE6 cell proliferation. As cell counting kit-8
(CCK-8) assay results showed in Figure 2B, activin A
significantly inhibited proliferation of LE6 cells in a
dose-dependent manner. Over a 72 h incubation period,
25 ng/ml activin A was sufficient to induce growth in-
hibition in LE6 cells. A maximum of 40% inhibition of
proliferation was achieved with 200 ng/ml activin A.
Accordingly, BrdU label index assay showed 200 ng/ml
Figure 1 Activin A and follistatin expression in the 2-AAF/PH model correlates with HPC proliferation. (A, E, I) Negative control. (B-D)
HPCs and interlobular or terminal duct cells showed positive immuno-reactivity (brown) to pan-CK monoclonal antibody. (×100 magnification).
(F-H) Expression of Activin A in 2-AAF/PH model (×100 magnification). (J-L) Expression of Follistatin in 2-AAF/PH model (×100 magnification).
(B, F and J) 2-AAF treated rats without PH; (C, G) 9th day after PH; (D, H) 15th day after PH; (K) 2th day after PH; (L) 4th day after PH. (M) The
change of HPCs counts in residual liver tissue following PH in 2-AAF/PH model. Expression of activinA (N) and follistatin (O) were detected by
IHC and IOD values were analyzed with Image-Pro Plus software (v. 5.0) and recorded in the histograms. (P and Q) Expression of activin βA
(P) and follistatin (Q) mRNA in residual liver tissue of partial hepatectomic rats treated with 2-AAF. Data were log-transformed and analyzed by
ANOVA for group difference (2-AAF/PH VS shame operation) and time difference (each time point VS 0 day) *P < 0.05 compared with initial time
point (0 day). #P < 0.05 compared with shame operation group; **P < 0.01 compared with initial time point. ##PP < 0.01 compared with sham
operation group. Bar = 100 um.
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sis in LE6 cells (Figure 2C). We next explored the effect
of activin treatment on induction of apoptosis in LE6cells using an AnnexinV/PI double label assay. As seen
in Figure 2D, 200 ng/ml activin A barely induced apop-
tosis in LE6 cells (Figure 2D).
Figure 2 Activin A inhibited proliferation of LE6 cells. (A) 2 × 105 LE6 cells/ were seed into 6-well plate and treated with serum free LE media
in the present of activin A for up to 48 hours. Cell media was harvested and concentration of TGF-β1 was detected by ELISA kit. The figure
showed result of one of three independent assays (B) LE6 cells were grown in 8% FBS LE media in the present or absence of activin A (25, 50,
100, 200, 300 ng/ml) for 72 hours. Cell proliferation was assessed by CCK-8 assay. Data showed result of one of three independent assays. (C and
D) LE6 cells were grown in 8% FBS LE media in the presence or absence of activin A (200 ng/ml) for 72 hours. Cell DNA synthesis was assessed
by BrdU incorporation assay using FACS (C). R2 = BrdU positive cells. Cell apoptosis was assessed by AnnexinV/PI assay using FACS (D). LL = Live
cells or annexin V and PI negative cells, LR = Early apoptotic cells or annexin V positive cells, UR = Late apoptotic and necrotic cells or annexin V
and PI positive cells, UL = Necrotic cells or PI positive cells. Bar chart showed the apoptosis rate (UR + LR) of control and activin treated LE6 cells.
The figure showed result of one of three independent assays.
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involved in activin A induced growth arrest in LE6 cells
To investigate the mechanism underling activin A-
induced growth arrest in LE6 cells, we treated LE6 cellswith activin A and detected a series of cell cycle related
proteins by western-blot. As shown in Figure 3A, the pro-
tein expression of the cyclin dependent kinase inhibitors
p15INK4B and p21WAF1/Cip1 increased dramatically after
Figure 3 Activin A activates SMAD signaling in LE6 cells. (A) LE6 cells were treated with activin A (200 ng/ml) for 6 h, 12 h, 24 h 48 h and
72 h, cell lysis was analyzed by western-blot using specific antibody to phosphorylated Rb, cyclinD1, cyclinE , p21WAF1/Cip1, p15INK4B p27Kip1, CDK2
and CDK4. β-actin was used as a loading control. (B) LE6 cells were treated with activin A (200 ng/ml) for 1 h, 6 h, 12 h and 24 h, cell lysis was
analyzed by western-blot using specific antibody to phosphorylated JNK1/2, ERK1/2 and p38. (C) LE6 cells were treated with activin A (200 ng/ml)
for 15 min, 30 min, 60 min and 120 min, cell lysis was analyzed by western-blot using specific antibody to phosphorylated SMAD2, SMAD3.
(D) LE6 cells were treated with activin A (200 ng/ml) for 60 min, cell lysis was incubated with anti-SMAD2/3 antibody and protein A/G agarose
overnight, then analyzed by western-blot using specific antibody to SMAD4. (E) LE6 cells were treated with activin A (200 ng/ml) for 15 min and
30 min, Nuclear and cytosolic fractions of cells were analyzed by western-blot using specific antibody to SMAD2/3.GAPDH or laminB was used as
loading control for cytosolic or nuclear fraction.
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sustained until 72 h after activin A stimulation.
Conversely, cyclin D1 and cyclin E expression de-
creased significantly 24 hours after exposure to acti-
vin A. Moreover, phosphorylation of Rb was also
inhibited by activin A. By contrast, activin A stimula-
tion was unable to affect the extent of p27Kip, cyclin-
dependent kinase 2 (CDK2) and cyclin-dependent
kinase 4 (CDK4) expression in LE6 cells. These re-
sults indicated that activin A suppressed downstream
targets cyclin D1 and cyclin E, induced expression of
p21WAF1/Cip1 and p15INK4B, and dephosphorylated Rb
protein all of which are likely to contribute to cell
growth arrest.Activin A failed to activate SMAD-independent
mitogen-activated protein kinase signaling in LE6 cells
Next we investigated the signaling pathways, activated
by activin A, that are required for growth arrest. The
principal pathways include the SMAD and mitogen-
activated protein kinase (MAPK) signaling cascades
[22]. First, we investigated the MAPK pathway by meas-
uring phosphorylated ERK1/2, JNK1/2 and p38MAPK
in LE6 cells by western-blot (Figure 3B). In the absence
of activin A stimulation, all three kinases were constitu-
tively phosphorylated in LE6 cells, and their phosphor-
ylation was not affected by activinA treatment. These
data suggest that MAPK signaling did not contribute to
activinA induced growth arrest in LE6 cells.
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induced growth arrest in HPCs
Next we looked at the SMAD pathway. LE6 cells were
incubated with the indicated dose of activin A, and then
phosphorylated SMAD2 and SMAD3 were analyzed
by western-blot. The data showed that SMAD2 and
SMAD3 were phosphorylated in a time-dependent man-
ner (Figure 3C). Phosphorylated SMAD2/3 forms a com-
plex with SMAD4 that shuttles into nucleus where they
regulate downstream gene transcription [22]. We detected
the formation and location of SMAD2/3/4 heterotrimer in
activin A treated LE6 cells. The co-immunoprecipitation
(co-IP) results demonstrated activin A induced SMAD2/
3/4 complex formation in LE6 cells (Figure 3D) and
western-blot results indicated that SMAD2/3 was pre-
dominantly located in nucleus in activin A treated LE6
cells, while conversely, SMAD2/3 was principally located
in cytoplasm in control cells (Figure 3E). These data con-
firm that activin A is able to activate the canonical SMAD
signaling pathway in LE6 cells.SMAD4 knockdown interrupts activin A-induced growth
arrest in LE6 cells
SMAD4 is the pivotal factor of canonical SMAD signal-
ing and its inactivation or deletion prevents SMAD sig-
naling. To further investigate the role of the SMAD
pathway in activin A-mediated growth arrest, LE6 cells
were infected with LV-shSmad4 to stable knockdown
endogenous Smad4. 3 of 4 Smad4 shRNA oligonucleo-
ties were able to deplete Smad4 expression by more
than 70% in LE6 cells and we chose the most effective
sequence sh3 for the following study (Figure 4A). Acti-
vin A stimulated SMAD2 and SMAD3 phosphorylation
(Figure 4B) but failed to induce formation of functional
SMAD2/3/4 heterotrimer in Smad4 knockdown LE6
cells (LE6-Smad4KD) (Figure 4C). These data indicated
that activin A-induced SMAD signaling could be
blocked by Smad4 knockdown.
We next explored the effect of depleting SMAD4 on
the ability of activin A to induce a growth arrest. LE6
cells transferred with an empty vector remained sensi-
tive to the effects of activin A, whereas LE6-Smad4KD
were resistant to activin A induced growth inhibition.
Then we examined the effect of activin A on the target
protein expression in LE6-Smad4KD cells (Figure 4E).
As expected, activin A induced expression of p21WAF1/
Cip1and p15INK4B in LE6-wild type (LE6-WT) cells, but
it could not induce these proteins in LE6-Smad4KD
cells. Consistent with this, activin A failed to down-
regulate cyclin E, or cyclin D1, or phosphorylated Rb in
LE6-Smad4KD cells. These results confirmed that
SMAD4-dependent signaling was crucially involved in
activin A induced growth inhibition in HPCs.Follistatin antagonizes activin A induced growth arrest
in HPCs
We found that follistatin mRNA increased in the early
phase of HPC-mediated liver regeneration, which was
about 6 h after PH and was followed by HPC proliferation.
These data indicated that follistatin could interrupt the
tonic growth inhibitory effect of activin A and in turn
stimulate HPC-induced liver regeneration. To confirm this
hypothesis, we treated LE6 cells with either activin A, or
activin A together with increasing-doses of follistatin or
follistatin alone, then analyzed the proliferation using
CCK-8 and BrdU incorporation assay. As seen in Figure 5A
and B, 400 ng/ml follistatin could fully reverse 200 ng/ml
activin A-induced growth arrest in LE6 cells. Nevertheless,
follistatin alone was unable to regulate cell proliferation.
Yet, follistatin therapy completely inhibited activin A-
induced phosphorylation of SMAD2 and SMAD3, restored
expression of cyclin D1 and cyclin E suppressed by activin
A and suppressed p21WAF1/Cip1 and p15INK4B expression
induced by activin A (Figure 5C and 5D). These data indi-
cated that follistatin could inhibit activin A induced growth
arrest.
Follistatin boosts HPC proliferation in vivo
In order to confirm the anti-proliferation role of activin
A in vivo, follistatin or normal saline (NS group) was in-
fused into portal vein immediately after 70% PH and
into the tail vein at 5, 10, 15 and 20 days after PH in 2-
AAF/PH rats. Compared to the NS group, more Pan-CK
positive hepatic progenitor cells were present in follistatin-
treated rats at 6, 9, 12, 15 days after PH. However, no sig-
nificant differences were detected in rats at 4 days and
21 days after PH (Figure 6B, 6C and 6G). Next we detected
the proliferation of cells in both groups by BrdU label assay.
More BrdU-positive cells were detected in the follistatin-
treated group at 4, 9, 12 days after PH. In addition, there
were no significant differences between these 2 groups at
15 and 21 days after PH (Figure 6E, 6F and 6H). To exclude
potential errors from body weight variations, liver/body
weight ratios were used to assess remnant liver restoration.
The ratio in the follistatin treated group was dramatically
higher than NS group at 9 days, 12 days and 15 days after
PH (Figure 6I). These data indicate that follistatin, an acti-
vin A antagonist, could enhance and prolong hepatic pro-
genitor cell amplification in vivo. These results confirmed
the anti-proliferation effect of activin A on hepatic progeni-
tor cells in vivo.
Discussion
In the present study, we examined the inhibitory effect of
activin A on the proliferation of hepatic progenitor cells
and revealed the mechanism. Activin A has been previ-
ously reported to inhibit DNA synthesis in mature hepato-
cytes [12,15-17,23,24]. After 2/3 PH, activin A expression
Figure 4 Knockdown of Smad4 blocks the anti-proliferative effect of activin A in LE6 cells. (A) SMAD4 expression was determined by
western-blot in LE6 cells after Smad4 knockdown (sh1, 2, 3, 4), and compared with control cells (wt) and vehicle cells (V). (B and C) Control cells,
vehicle and Smad4 knockdown LE6 cells (LE6-Smad4KD) were treated with or without 200 ng/ml activin A. Phosphorylated SMAD2 was detected
by western-blot (B) and SMAD2/3/4 complex formation was detected by co-immuno precipitation (C). (D) shSmad4-LE6 cells were treated with
or without 200 ng/ml activin A and their proliferation assessed by CCK-8 and BrdU incorporation assay. c: control, v: vehicle, sh3: LE6-smad4KD.
(E) Indicated cells were treated with or without 200 ng/ml activin A, phosphorylated Rb, cyclinD1, cyclinE , p21WAF1/Cip1and p15INK4B were
analyzed by western blotting.
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period, whereas activin A expression is significantly in-
duced in the later stages when regeneration is slowing
down [25]. We observed a similar behavior in the 2-AAF/
PH HPC-mediated liver regeneration model. Furthermore,
DNA synthesis was enhanced in intact rat liver in which
activin A signaling was temporary disrupted by adminis-
tration of follistatin [26-28]. Our data demonstrated follis-
tatin enhanced proliferation of HPCs in the 2-AAF/PH
model. All these findings indicate that a basal amount of
activin A exists in the intact liver to tonically inhibit ma-
ture hepatocyte or HPC-mediated proliferation and main-
tained adequate liver weight. Moreover, it plays an
important role in termination of liver regeneration. Once
the balance between follistatin and activin A is broken, for
example, in the PH or 2-AAF/PH model, hepatocyte or
hepatic progenitor cells escape from the anti-proliferative
effect of activin A and start to proliferate. Once the liver
mass is restored, the restoration of activin A expression
again terminates liver regeneration, irrespective of whether
the regeneration is mediated by hepatocytes or hepatic
progenitor cells.
Ooe et al. [29] described a subpopulation of rat hepato-
cytes (small hepatocyte, SH) that have high growth poten-
tial in culture. Recent studies indicated that SH are
posterity of oval cells: Ichinohe and Xiang reported that
oval cells could differentiate into mature hepatocyte via
SH [30-32]. Consistent with our work, Ooe found activin
A suppresses the proliferation of SH, but cannot induce
apoptosis of SH. Both studies demonstrate that the activin
pathway is a key negative regulator of hepatic progenitor
proliferation. However, Ooe reported activin B suppressed
the proliferation of SH in an autocrine manner. Thecontribution of activin B and other members of the activin
family to the proliferation of oval cells needs further inves-
tigation. Menthena et al. [33] reported fetal liver progeni-
tor cells were resistant to activin A because of their lack
of activin A receptors. The inconsistency between both
Menthena and Ooe’s studies and our results may be due
to different activin A receptor expression. In our hands
and in Ooe’s work activin receptors are abundantly
expressed in adult hepatic progenitor cells. This fact sug-
gests that there are major differences in the regulation of
cell growth between adult and fetal liver progenitor cells.
The anti-proliferative effects of activin A are likely to
be due to the activation of signaling pathways that tar-
get cell cycle-related proteins. Activin A enhanced ex-
pression of p15INK4B, reduced cyclin A expression and
reduced phoshorylation of the Rb protein in breast can-
cer cells [34]. Hepatoma cells respond to activin by up-
regulating the expression of p21WAF1/Cip1, p16 and
p15INK4B proteins that suppress the cyclinD-CDK4/6
and cyclinE-CDK2-mediated phosphorylation of the Rb
protein [23,35,36]. Activin A could down-regulate cyclin
D, cyclin E and CDK4, all of which are important con-
tributors to Rb protein phosphorylation [34,36]. The de-
phosphorylation of Rb leads to cell cycle arrest and
inhibtion of cell proliferation. Our study demonstrated
that activin A stimulated the expression of p15INK4B
and p21WAF1/Cip1 and inhibited the expression of cyclin
D1 and cyclin E protein leading to the inhibition of Rb
protein phosphorylation. These data indicated that
p15INK4B, p21WAF1/Cip1, cyclin D1 and cyclin E were all
associated with regulating the degree of Rb protein
phosphorylation during activin A-induced cell prolifera-
tion arrest in HPCs.
Figure 5 Follistatin blocks the growth arrest induced by activin A in LE6 cells. (A) LE6 cells were treated with activin A (200 ng/ml) in the
presence or absence of the indicated doses of follistatin (25, 50, 100, 200, 400, 600 ng/ml). Cell proliferation was detected by CCK-8 assay. (B) LE6
cells were grown in LE media in the presence or absence of activin A (200 ng/ml), follistatin (400 ng/ml) or activin A (200 ng/ml) plus follistatin
(400 ng/ml). DNA synthesis was detected by BrdU incorporation assay using FACS. (C) LE6 cells were treated with or without activin A (200 ng/ml),
follistatin (400 ng/ml) or activin A (200 ng/ml) plus follistatin (400 ng/ml) for 30 min. Phosphorylated SMAD2/3 was detected by western-blot. (D) LE6
cells were treated with either media alone, activin A (200 ng/ml), follistatin (400 ng/ml) or activin(200 ng/ml) plus follistatin (400 ng/ml). Then
phosphorylated Rb, cyclinD1, cyclinE, p21WAF1/Cip1and p15INK4B were analyzed by western-blot.
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of cells via SMAD signaling. The activation of the activin
A/SMAD pathway results in the formation and nuclear lo-
cation of the SMAD2/3/4 complex and regulates the ex-
pression of known targets including c-myc, cdc25A,
p15INK4B, p21WAF1/Cip1, p16 INK4A, cyclinA, cyclinD1 and
cyclinE [37-39]. However, other studies reported that not
only SMAD, but also p38MAPK and ERK signaling con-
tribute to activin A-induced proliferation arrest or apop-
tosis [40,41]. Our study confirmed that activin A activated
SMAD pathway (SMAD2/3 phosphorylation, SMAD2/3/4
complex formation and nuclear location), and regulated
downstream targets expression (p15INK4B, p21WAF1/Cip1,
cyclin D1 and cyclin E) in HPCs. Destruction of SMAD
signaling by SMAD4 knockdown fully restrained activin
A-induced proliferation arrest in LE6 cells. Moreover,
activin A failed to change the phosphorylation level of
p38 and ERK in LE6 cells. These data indicate that
the anti-proliferation effect of activin A is SMAD-
dependent. Nevertheless, we noticed a high basal levelof phosphorylated p38, ERK and JNK in serum-starved
LE6 cells, which might be related to the autocrine produc-
tion of growth/survival factors, such as hepatocyte growth
factor (HGF) and epidermal growth factor (EGF). These
autocrine signals may be responsible for the insensitivity of
MAPK pathways to respond to the addition of exogenous
activin A. Furthermore, the over-activation of MAPK
might be also responsible for our observation that LE6 cells
were more insensitive to activin A-induced growth arrest
and apoptosis compared to previously reported studies in
mature hepatocytes [35,42].
The biological function of follistatin has been based on
its reported ability to bind to activins with a high affinity.
The picomolar affinity of follistatin molecules for activin
dimmers forms the basis for follistatin to act as a potent
extracellular regulatory mechanism in which activins are
tightly bound and cannot bind to activin receptors and
trigger downstream signaling [43]. Ooe et al. reported fol-
listatin facilitates the proliferation of small hepatocytes by
blocking activin A signaling in an autocrine manner.
Figure 6 Follistatin accelerated oval cell proliferation in vivo. (A and D) negative control; Pan-CK positive hepatic progenitor cells (B and C,
100 ×magnification) and BrdU positive proliferating cells (E and F, 200 ×magnification) in normal sailine (NS) or follistatin treated (FST) 2-AAF/PH
rats 6 day after PH were determined by immuno-histochemistry. Comparison of the number of Pan-CK positive hepatic progenitor cells (G), BrdU
positive proliferating cells (H) and Liver /body weight ratio (I) in two groups of animals. Data represent mean ± SD, n = 4–6, *P < 0.05 compared
to NS group. Bar = 100 um.
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hepatocyte growth in vivo. In the 2-AAF/PH model, up-
regulation of follistatin in rat livers decreased the activity
of activin A signaling and rendered cells resistant to acti-
vin A-induced growth arrest. Administration of follistatin
accelerated oval cell expansion in the 2-AAF/PH model.
Yet, follistatin alone was unable to affect the proliferation
of LE6 cell. Taken together, our data indicated follistatin
regulated oval cell proliferation only by blocking activin A.
Our data also indicated that although follistatin itself did
not have the ability to work as mitogen, it could neutralize
the growth arrest of activin A and facilitated the prolifera-
tion of hepatic progenitor cells.
In conclusion, our study showed the compact correlation
between activin A signaling and HPC proliferation. Further-
more, we found activin A inhibited cellular proliferation in
HPC cell lines via the canonical SMAD pathway. Activin Aup-regulated p15INK4B and p21WAF1/Cip1, down-regulated
cyclin D1 and cyclin E. Consistent with our results, it is re-
ported that reduced phosphorylation of Rb protein, is asso-
ciated with a growth arrest in HPCs. Taken together, activin
A plays an important role in negative regulation of HPCs
proliferation through a SMAD-dependent pathway.Material and methods
Animal model
Adult male Sprague–Dawley rats (180-200 g) were used.
They were bred and maintained on standard laboratory
chow using 12-hour light/dark cycles. The body weights
were recorded daily. The rats were treated according to
the guidelines of the council for International Organiza-
tions of Medical Sciences, as required by the ethics com-
mittee of Tongji Medical College.
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scribed [44]. Briefly, all rats received oral gavages of 2-
AAF (Sigma-Aldrich MO USA) dissolved in polyethylene
glycol (mol. wt. 400, Sigma-Aldrich MO USA) for up to
11 days at the dose of 15 mg/kg, and then two-thirds PH
was performed under pentobarbitone anaesthesia in the
fifth day. Control sham operation consisted of laparotomy
without PH and briefly handling the liver. Five rats were
killed at 6 h, 1d, 2d, 4d, 6d, 9d, 12d, 15d and 21d after ini-
tiation of PH. Liver tissue samples were fixed in 4% para-
formaldehyde and processed to 4 μm thick sections for
immunohistochemistry or immediately stored in −80°C
for real-time PCR.
Follistatin administration
After 70% PH, 1microgram follistatin dissolved in 0.5 ml
natural saline was infused into portal vein using 29G insu-
lin syringe as mentioned by Kogure [14]. In the normal sa-
line (NS) group, the same volume of normal saline was
infused into portal vein. The same dose of follistatin or sa-
line was injected into tail vein at 5, 10, 15 and 20 days after
PH.4-6 rats were killed at 4d, 6d, 9d, 12d, 15d, 21d after
initiation of PH, liver weights and body weights were re-
corded. Restoration of liver weights was expressed as per-
centage of regenerated liver weight to body weight. For
BrdU incorporation assay, two hours before sacrifice,
animals were injected intraperitoneally with 50 mg 5-
bromo-2-deoxyuridine (BrdU) per kg body weight. Liver
tissue samples were fixed in 4% paraformaldehyde for
immunohistochemistry.
Immunohistochemistry
Sections were deparaffinised as described previously. Anti-
gens were retrieved by incubating with proteinase K
(DakoCytomation, Glostrup, Denmark) at 4°C for 5 min
or by undergoing microwave heat antigen retrieval in
10 mM Tris Base, 1 mM EDTA Solution, pH 9.0; For
BrdU incorporation assay, sections were incubated in 4 N
HCL for 20 min at 37°C, after rinsing in 0.1 M borax solu-
tion for 5 min and PBS for 3 × 5 min, sections were incu-
bated with 0.1% trypsin for 10 min at 37°C. Endogenous
peroxidase activity was blocked with 3% H2O2 in
methanol. Then sections were incubated with rabbit anti-
pan-cytokeratin antibody (1:50, DAKO, Denmark), mouse
anti-activin A antibody (1:100, R&D, USA), rabbit anti-
follistatin antibody (1:50, ProteinTech Group, China) or
mouse anti-BrdU antibody (1:400, DAKO Denmark) at 4°C
overnight. For negative control, antibodies were replacedTable 1 The primer sequences and melting temperature(Tm)
Gene Sense
Activin βA 5'-TGATGTGCGGATTGCTTGTG-3'
Follistatin 5'-AGCTTGCTGGGCAGATCCATT-3'by homologous serum. Sectionswere washed with PBS and
subsequently incubated with goat anti-mouse EnVision kit
(DAKO Denmark) at room temperature. Peroxidase activ-
ity was detected using 3'3'diaminobenzidine tetrahydro-
chloride (DAB, DAKO Denmark) and counterstained with
haematoxylin (Sigma-Aldrich MO USA). Digital images
were prepared by Digital Sight ACT-1 for L-1 Software
(Nikon Japan). Positively stained cells were counted as de-
scribed previously with slight changes [30,45]. In brief,
BrdU positive cells and hepatic progenitor cells positive for
Pan-CK were counted in 20 adjacent non-overlapping
fields in one section, at 400× magnification. 5 non-serial
sections were counted for each rat. The expression of fol-
listatin and activinA were annualized as described previ-
ously [46]. In brief, average value of IOD was obtained by
analyzing five fields at 200× magnification per slide with
Image-Pro Plus software (V.5.0).
Real-time PCR
Total RNA was extracted from liver tissue sample using
Trizol regent (Invitrogen, CA USA) according to manufac-
turer’s directions. Equal amounts of RNA were used for
generation of first strand cDNA using PrimeScript® RT re-
agent Kit (Takara Bio Inc, Japan). Primers used to detect
activin βA [Gene Bank: NM_017128.2], follistatin [Gene
Bank: NM_012561.1] and β-actin were designed using the
primer design software ‘Primer 5.0’ (Table 1) and purchase
from suppliers (Invitrogen, CA USA). Real-Time PCR was
performed on ABI Prism 7000 Sequence Detection System
with ABI Prism 7000 SDS Software 1.0 in 96-well format
and 25 μL reaction volume per well (Applied Biosystems,
CA USA) with SYBR Green Real-time PCR Master Mix-
PLUS (TOYOBO, Japan) according to the manufacturers’
introductions. The Ct values of the selected genes were
first normalized with β-actin from the same sample, and
then the relative expression of each gene was analyzed
using 2-ΔΔCt Method.
Cell culture
Hepatic progenitor cell line LE6, derived from rats that
were maintained on a choline-deficient diet for 6 weeks
[47-49], were a kind gift from Prof. Nelson Fausto. Cells
were grown in DMEM/F10 (Thermo Scientific HyClone,
Utah USA) supplemented with 10% fetal bovine serum
(FBS, Thermo Scientific HyClone, Utah USA), 0.5 mg/L in-
sulin, 1 mg/L hydrocortisone (Sigma-Aldrich, MO USA)
and 50 mg/L gentamicin(Invitrogen, CA USA) (LE medium)




Table 2 Target sequences of specific shRNA oligoes to rat
smad4
Marker Gene Target sequence GC%
Sh1 Smad4 GCTACTTACCACCATAACA 42.10%
Sh2 Smad4 GGTAGGAGAGACATTTAAA 36.84%
Sh3 Smad4 GGAGTGCAGTTGGAGTGTA 52.63%
Sh4 Smad4 GCTGAAAGAGAAGAAAGAT 36.84%
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Rat Smad4-specific shRNA lentivirus and random shRNA
lentivirus were purchased from GeneChem Co Shanghai
China (Table 2) [Gene Bank: NM_019275]. LE6 cells were
incubated with Smad4-specific shRNA lentivirus particles
at a ratio of 25 particles to 1 cell, in the presence of 8 μg/ml
hexadimethrine bromide to improve transduction effi-
ciency. Random oligo shRNA lentivirus was used as con-
trol. Stable Smad4 knock down LE6 cells were selected by




























Mouse anti-laminB 1:5shRNA sequences were detected by western-blot and the
most efficient sequence was used for further research.
Activin A and TGF-β1 enzyme-linked immunosorbent assay
Supernatants were collected from confluent LE6 cells
treated with or without activin A and tested in triplicate
for activin A and TGF-β1 concentrations using rat acti-
vin A ELISA kit and rat TGF-β1 ELISA kit (R&D sys-
tem, MN USA). 3 independent assays were performed
with at least 3 replicates.
Proliferation and apoptosis assay
Growth property of LE6 cells was tested by CCK-8 assay
according to manufacturer’s introductions (Beyotime In-
stitute of Biotechnology, China). Briefly, LE6 cells were
seeded in triplicates in 96-well plate at 800 cells/100ul
LE medium. Cells were either stimulated with or without
various concentrations of activin A (PeproTech Inc, NJ
USA), follistatin (R&D system, MN USA) or activin Aion Manufacture
00 Cell Signaling Technology, USA
00 Cell Signaling Technology, USA
00 Cell Signaling Technology, USA
00 Cell Signaling Technology, USA
00 Epitomics, China
Santa Cruz Biotechnology Inc, USA
00
0
00 Cell Signaling Technology, USA
00 Cell Signaling Technology, USA
00 Cell Signaling Technology, USA
00 Cell Signaling Technology, USA
00 Cell Signaling Technology, USA
00 Cell Signaling Technology, USA
00 Cell Signaling Technology, USA
00 Santa Cruz Biotechnology Inc, USA
00 Epitomics, China
00 Epitomics, China




00 Santa Cruz Biotechnology Inc, USA
00 Santa Cruz Biotechnology Inc, USA
000 Santa Cruz Biotechnology Inc, USA
00 Santa Cruz Biotechnology Inc, USA
00 Proteintech Group, USA
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incubation at 37°C, cell viability was determined by col-
orimetric assay using CCK-8. 3 independent assays were
performed with at least 3 replicates.
For BrdU incorporation assay, LE6 cells were planted
in triplicate in 6-well-plate at 1.5 × 105 cells/well. Cells
were incubated with activin A (200 ng/ml), follistatin
(400 ng/ml) or activin A (200 ng/ml) plus follistatin
(400 ng/ml) for 72 hours and 10uM BrdU (Sigma-
Aldrich, MO USA) were added at the last 30 min. Cells
were harvested and fixed by ice cold 70% ethanol. After
treated with 4 N HCL and 0.2 M borax, cells were incu-
bated with mouse anti-BrdU monoclonal antibody
(1:100, Santa Cruz Biotechnology, CA USA) for 1 hour
at 4°C and FITC labeled goat anti-mouse antibody (1:100,
Jackson ImmunoResearch Laboratories Inc, PA USA) for
1 hour at 37°C. Then BrdU incorporation rate was ex-
amined by BD FACSCanto™ Flow Cytometry System
(Becton, Dickinson and Company, NJ USA). For apop-
tosis assay, LE6 cells were incubated with indicated cell
factors for 4 days, and then the cells were harvested and
stained by FITC-labeled Annexin V/PI apoptosis assay
kit (KeyGEN Biotech, China). The degree of apoptosis
was tested by FACS. 3 independent assays were per-
formed with at least 3 replicates.Western blotting and co-immunoprecipitation
After treatment with indicated cell factors, LE6 cells or
LE6-shSmad4 cells were harvested and incubated in ice-
cold RIPA lysis (Beyotime Institute of Biotechnology,
China) plus protein inhibitor cocktail (Roche Ltd,
Switzerland) for whole cell protein, and NE-PER Nuclear
and Cytoplasmic Extraction Reagents (Thermo Fisher Sci-
entific Inc, MA USA) for nuclear and cytoplasmic frac-
tionation. Then the protein content was detected by BCA
kit (Thermo Fisher Scientific Inc, MA USA). 60ug lysate
was run on 15% or 10% PAGE polyacrylamide gel, trans-
ferred onto PVDF membranes (Roche Ltd, Switzerland).
After blocked in 5% BSA in TBS at room temperature for
1 hour, the membranes were incubated with primary anti-
body at 4°C overnight. The details of primary antibodies
were showen in Table 3. Then the membranes were
washed with 0.1% tween-20 in TBS (TBST) and incubated
with horseradish peroxidase-conjugated secondary or al-
kaline phosphatase antibody secondary antibody at 37°C
for 1 hours (1:5000, Jackson Immuno Research Laborator-
ies Inc, PA USA). Then the membranes were washed with
TBST 3 times for 45 mins. Protein band immunoreac-
tivity was revealed by chemiluminescence according to
the manufacturer’s instructions (Thermo Fisher Scien-
tific Inc, MA USA) and detected using an Alpha Inno-
tech Fluorochem Imaging system (Alphatron Asia Pte
Ltd, Singapore).For co-immunoprecipitation, LE6 cells or LE6-shSamd4
cells were serum-starved for 12 hours, and then treated
with 200 ng/ml activin A for 1 hour. Cells were harvested
and incubated with IP-lysis buffer (Beyotime Institute of
Biotechnology, China). Cell lysis were incubated with
mouse anti-Smad2/3 polyclonal antibody (1:50, Santa
Cruz Biotechnology, CA USA) at 4°C for 2 hours, followed
by incubation with 20ul protein A/G agarose (Santa Cruz
Biotechnology, CA USA) at 4°C overnight. Immunopre-
cipitates were washed 4 times with the lysis buffer and
analysis by immunoblot using rat anti-Smad4 monoclonal
antibody (1:2000, Epitomics, CA USA).
Statistical analyses
Data were expressed as mean values ± standard devi-
ation. The related expression of genes was log trans-
formed and variation with time assessed by ANOVA.
The data of AnnexinV/PI assay, BrdU incorporation
assay (both FACS and immunohistochemistry, except for
Figure 5B) and liver/body weight ratio were analyzed by
student’s t-test. ELISA, cell viability data and BrdU in-
corporation data (Figure 5B) were analyzed by unpaired
student’s t-test or ANOVA by SPSS 11.5. A difference in
P values of <0.05 was considered significant.
Abbreviation
MAPK: Mitogen activated protein kinase; 2-AAF: 2-acetylaminofuorene;
PH: Partial hepatectomy; TGF-β: Transforming growth factor β; ActR II A/
B: Activin type II receptor A/B; ALK4: Activin A receptor-like kinase 4;
CCK-8: Cell counting kit-8; R-smad: Receptor-regulated smad; co-smad: Common
mediator Smad; pan-CK: Pan-cytokeratin; HPC: Hepatic progenitor cell;
CDK: Cyclin-dependent kinase; HGF: Hepatocyte growth factor; EGF: Epithelial
growth factor; BrdU: 5-bromo-2 –deoxyuridine; Ct: Cycle threshold.
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